A Phase II Study of HIV-Specific T Cells for HIV+ Patients with Lymphoma Receiving Chemotherapy Followed by Autologous Stem Cell Transplantation


Full Title

Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST (BMT CTN) (NMDP)


Chemotherapy and autologous stem cell transplantation are treatments for some people with lymphoma. During an autologous stem cell transplant, the stem cells in the body that produce blood are removed, and then returned after treatment with chemotherapy.

In this study, researchers want to see if it is possible to modify a patient’s white blood cells called T cells to make them recognize HIV. The T cells are trained to target special proteins on a patient’s cells that are infected with HIV. These HIV-specific T cells will be given to people who are taking medication for HIV, have lymphoma, and will be undergoing autologous stem cell transplantation. It is hoped that the HIV-specific T cells will help the body fight HIV during transplantation.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have lymphoma that has come back or continued to grow despite treatment. Types of lymphoma treated in this study will include diffuse large B-cell lymphoma; composite lymphoma with greater than 50 percent diffuse large B-cell lymphoma; mediastinal B-cell lymphoma; immunoblastic, plasmablastic, Burkitt, or high-grade B-cell lymphoma; or classical Hodgkin lymphoma.
  • Patients must be taking antiretroviral treatment for HIV and have an undetectable viral load.
  • Participants must be planning to receive high-dose chemotherapy and autologous stem cell transplantation.
  • This study is for people age 15 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Parastoo Dahi at 646-608-3733.




Phase II (phase 2)



ClinicalTrials.gov ID